Brief: Marinomed Biotech Signs New Agreement For Carragelose In South Korea
April 12 (Reuters) - MARINOMED BIOTECH AG MARI.VI :
* SIGNS NEW AGREEMENT FOR CARRAGELOSE IN SOUTH KOREA
* CARRAGELOSE, SHOWN TO EFFECTIVELY INACTIVATE SARS-COV-2
WILDTYPE
AND COMMON VARIANTS, IS CURRENTLY AVAILABLE IN MORE THAN 40
COUNTRIES WORLDWIDE
* MARINOMED WINS HANMI PHARMACEUTICAL CO., LTD. AS PARTNER
FOR
DISTRIBUTION OF CARRAGELOSE NASAL
Source text for Eikon: ID:nEQzwMsDa
Further company coverage: MARI.VI
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hanmi Pharm
See all newsBrief: Hanmi Pharm To Cancel 28 Billion Won Worth Of Own Shares
Brief: Hanmi Pharm Q3 Operating Profit 37.8 Billion Won, Down 31.3% From Year Earlier
Brief: Hanmi Pharm Co Signs License Out Agreement With Genetech Inc. In U.S.
Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
Brief: Hanmi Pharm Co Ltd Wins 53 Billion Won Order